Loading...
XJPX
3750
Market cap47mUSD
Dec 05, Last price  
833.00JPY
1D
1.83%
1Q
-10.91%
Jan 2017
230.56%
IPO
-73.23%
Name

Cytori Cell Research Institute Inc

Chart & Performance

D1W1MN
XJPX:3750 chart
P/E
P/S
60.86
EPS
Div Yield, %
Shrs. gr., 5y
5.87%
Rev. gr., 5y
-36.46%
Revenues
122m
-92.17%
1,180,000,0001,388,292,0001,335,578,0002,144,712,0001,560,388,000122,204,000
Net income
-2.14b
L
319,000,000-831,863,000-77,633,000-1,059,941,000138,155,000-2,140,085,999
CFO
-987m
L-14.34%
531,000,000-82,897,000-187,784,000-39,518,000-1,152,230,000-987,038,000
Dividend
Mar 27, 201920 JPY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Cytori Cell Research Institute, Inc., engages in the research, development, production, and sale of cell therapy related medical devices in Japan. The company sells cell therapy kits, as well as engages in the research and development of cell therapy technology, etc. Its products pipeline includes ECCI-50 for the treatment of male stress urinary incontinence and liver cirrhosis; and Cyt-006 to prevent postoperative adhesion for primary rectal cancer. The company is also conducting clinical trials/research on cell therapy for a range of diseases and applications, including anterior cruciate ligament repair, bone repair, burn scars, chronic wound healing, critical limb ischemia, anal and Crohn's disease fistulas, erectile dysfunction, etc. It also invests in, owns, develops, leases, and manages real estate projects and hotels; and provides real estate brokerage services. The company was formerly known as FRACTALE Corporation. Cytori Cell Research Institute, Inc. was incorporated in 2004 and is headquartered in Tokyo, Japan.
IPO date
Oct 01, 2004
Employees
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFY
2025‑032024‑032023‑032022‑032021‑032020‑03
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT